Deep vein thrombosis (DVT) and pulmonary embolism (PE) — together called venous thromboembolism (VTE) — are serious, potentially fatal conditions that affect thousands of South Africans each year. DVT occurs when a blood clot forms in a deep vein (typically the leg), and PE occurs when a clot travels to the lungs. Both conditions are PMB-covered for acute treatment, but the choice of long-term anticoagulation — and how your scheme funds it — has significant financial implications.
What Is DVT and What Is PE?
DVT (Deep Vein Thrombosis): A clot forms in a large deep vein, most commonly in the calf, thigh, or pelvis. Symptoms: swollen, painful, warm, or red leg — often only one leg. Many DVTs are asymptomatic and discovered incidentally.
PE (Pulmonary Embolism): Part or all of the DVT clot breaks off and travels via the bloodstream to the pulmonary arteries in the lungs. Symptoms: sudden breathlessness, chest pain (often pleuritic — worse with breathing), rapid heart rate, coughing up blood (haemoptysis), and — in massive PE — collapse or cardiac arrest.
Massive PE with haemodynamic instability (hypotension, shock) is immediately life-threatening — call 10177.
Risk Factors Relevant to South Africa
VTE risk is elevated in South Africa due to several population-specific factors: - HIV/AIDS: HIV is a prothrombotic state — HIV-positive individuals have 2–10× higher VTE risk - Cancer: Hypercoagulable states in active malignancy; oncology treatment (chemotherapy, hormonal) - Major surgery: Joint replacement, abdominal surgery, obstetric surgery — particularly in the weeks following - Antiphospholipid syndrome: More prevalent in SLE (which is more prevalent in SA women of colour); causes recurrent thrombosis - Long-haul travel: Johannesburg–London or other intercontinental flights (9–11 hours); economy class, dehydration, immobility - Pregnancy and post-partum: Elevated hormonal and mechanical risk; particularly relevant in SA's obstetric context - Obesity, smoking, oral contraceptive pill: Standard modifiable risk factors
Is DVT/PE a PMB Condition?
Yes. DVT and PE are PMB Diagnosis and Treatment Pairs. Acute hospital admission, anticoagulation initiation, and diagnostic investigations must be funded by your scheme.
Acute treatment (hospitalisation): - Diagnostic ultrasound for DVT (Doppler ultrasound of legs) - CT pulmonary angiography (CTPA) for suspected PE - Anticoagulation initiation - Thrombolysis or surgical embolectomy for massive PE (life-saving; PMB emergency)
Ongoing anticoagulation: Once past the acute hospital phase, ongoing anticoagulation moves to your day-to-day benefit. This is where costs vary significantly depending on the medication chosen.
Warfarin vs DOAC — The Key Treatment Decision
Warfarin (first-generation anticoagulant): - Very inexpensive: R20–R80/month for warfarin tablets - Requires INR monitoring: monthly blood test R80–R200, plus occasional GP or anticoagulation clinic visits - Dietary restrictions (vitamin K interactions) - Drug interactions are extensive - Annual total: R3,000–R8,000 for medication + monitoring
DOACs (Direct Oral Anticoagulants): - Rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), edoxaban - No regular monitoring required — convenient - Fewer drug interactions, no dietary restrictions - Higher cost: R600–R1,200/month - Annual total: R7,200–R14,400 in medication alone
SA Medical Aid reality: DOACs are not universally on scheme formularies or may require step-therapy (try warfarin first). Some comprehensive plans cover DOACs under the chronic medication benefit; others require special motivation.
Call your scheme: "Is rivaroxaban (or apixaban) on my formulary? Is it covered under my acute or chronic medication benefit? Is there a step-therapy requirement?"
How Does Medical Aid Cover DVT/PE?
| Service | PMB/CDL? | Typical cover | Notes |
|---|---|---|---|
| Emergency ER assessment | Yes — PMB | Hospital benefit | |
| Doppler ultrasound (DVT diagnosis) | Yes — PMB (acute) | Radiology benefit | |
| CTPA (PE diagnosis) | Yes — PMB (acute) | Radiology/hospital benefit | |
| D-dimer and clotting tests | Yes — PMB (acute) | Pathology benefit | |
| Hospital admission (acute anticoagulation) | Yes — PMB | Hospital benefit | Usually 2–5 days |
| Thrombolysis (massive PE — life-saving) | Yes — PMB emergency | Hospital benefit (ICU) | |
| Inferior vena cava (IVC) filter (selected cases) | Yes — PMB | Hospital benefit | |
| Warfarin (ongoing) | No | Day-to-day chronic | R20–R80/month |
| INR monitoring (warfarin patients) | No | Pathology benefit | Monthly; R80–R200/test |
| DOAC (rivaroxaban, apixaban — ongoing) | No | Day-to-day — check formulary | R600–R1,200/month |
| Thrombophilia testing (factor V Leiden, protein C/S, antiphospholipid) | No | Pathology benefit | Indicated for unprovoked/recurrent VTE |
| Haematologist consultation (recurrent VTE) | No | Day-to-day | Shortfall likely |
| Compression stockings (post-thrombotic syndrome) | No | OOP | R400–R1,200 per stocking pair |
Duration of Anticoagulation — Financial Implications
Provoked DVT/PE (clear trigger: surgery, trauma, immobility): 3–6 months of anticoagulation, then stop.
Unprovoked DVT/PE (no clear trigger): 6–12 months, reassess; many patients treated indefinitely.
Recurrent VTE or thrombophilia: Indefinite anticoagulation.
Annual DOAC cost: R7,200–R14,400. For indefinite treatment, this is a significant recurring cost from your day-to-day benefit. If your MSA is small, this can deplete it rapidly. Plans with insured day-to-day benefits (ATB) or larger MSAs handle this better.
Gap Cover Relevance
Gap cover is relevant for: - Acute hospital admission for DVT/PE — haematologist or specialist physician shortfall - IVC filter insertion — interventional radiologist shortfall - Thrombolysis for massive PE — ICU anaesthesiologist shortfall
Key Questions to Ask Your Scheme
- Is my DOAC of choice on your formulary? Name the specific drug — "rivaroxaban" or "apixaban."
- Is DOAC therapy covered under my chronic medication benefit? For indefinite treatment, chronic dispensing (3-month supply) reduces dispensing fees.
- Is thrombophilia testing covered under my pathology benefit? For an unprovoked PE, factor V Leiden, protein C/S/antithrombin, and antiphospholipid testing is clinically indicated.
- Does my plan have an ATB for the periods when my MSA is depleted? High ongoing medication costs are a day-to-day issue.
Talk to Eldon
Ongoing anticoagulation for VTE is a long-term day-to-day cost. The Check shows what each plan on our panel pays for this, side by side, and Eldon advises from there.
See which plans pay for VTE management →